ArticleJournal of pain and symptom management2025
Providers' Barriers to Buprenorphine Prescribing for Cancer-Related Pain.
Article in Journal of pain and symptom management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFull-agonist opioids are standard for treating cancer-related pain. However partial-agonist opioids (e.g., buprenorphine) are promising treatments with fewer side effects and a stronger safety profile. However, it is unclear how oncology and palliative care providers (Medical Doctors, Advanced Practice Providers, etc.) perceive prescribing of buprenorphine for cancer-related pain.
methodsParticipants (N = 42; 50% oncology) at a single healthcare system with multiple hospitals completed a one-time web-delivered survey assessing reported opioid prescribing patterns and barriers to buprenorphine prescribing for cancer-related pain. Independent samples t- and chi-square tests compared palliative and oncology providers' opioid prescribing and barriers to buprenorphine use; we examined how barriers related to intentions to prescribe buprenorphine with correlations.
resultsMost participants reported awareness of buprenorphine for cancer-related pain (81%), and that buprenorphine is effective for treating cancer-related pain (80%), but few reported prescribing it (oncology 0%; palliative 5%). Oncology providers reported lack of knowledge about buprenorphine prescribing. Palliative care providers reported opioid stigma (61.7%) and patients' difficulty obtaining buprenorphine (47.6%) were barriers. Prescribing participants' future intentions to prescribe buprenorphine for cancer-related pain was significantly associated with endorsement that buprenorphine is as effective as (r = .53, P = .005), and that it causes fewer side-effects relative to (r = .59, P < .001) other opioids. DISCUSSION: Our study identified knowledge gaps in cancer care teams about buprenorphine for cancer-related pain. Future research should consider education for oncology teams on buprenorphine, and how oncology and palliative care teams can benefit from working together to reduce stigma when communicating with patients about buprenorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.